SECUADO
SECUADO (asenapine) is an atypical antipsychotic medication. It is specifically indicated for the treatment of schizophrenia in adult patients. As a member of the atypical antipsychotic class, it serves as a therapeutic option for managing this chronic psychiatric condition in the adult population.
How SECUADO Works
The exact mechanism of action of asenapine in treating schizophrenia is not fully understood. However, its therapeutic efficacy is believed to be mediated through its activity at specific biological targets. The drug functions as an antagonist, blocking both D2 and 5-HT 2A receptors to produce its clinical effects.
Details
- Status
- Prescription
- First Approved
- 2019-10-11
- Routes
- TRANSDERMAL
- Dosage Forms
- SYSTEM
SECUADO Approval History
What SECUADO Treats
1 indicationsSECUADO is approved for 1 conditions since its original approval in 2019. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Schizophrenia
SECUADO Boxed Warning
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SECUADO is not approved for the treatment of patients with dementia-related psychosis [ see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psyc...
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SECUADO is not approved for the treatment of patients with dementia-related psychosis [ see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SECUADO is not approved for the treatment of patients with dementia-related psychosis. ( 5.1 )
Drugs Similar to SECUADO
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
SECUADO FDA Label Details
ProIndications & Usage
FDA Label (PDF)SECUADO is indicated for the treatment of adults with schizophrenia [ see Clinical Studies ]. SECUADO is an atypical antipsychotic indicated for the treatment of adults with schizophrenia.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. SECUADO is not approved for the treatment of patients with dementia-related psychosis [ see Warnings a...
SECUADO Patents & Exclusivity
Patents (54 active)
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.